Cyberknife treatment for low and intermediate risk prostate cancer

Autor:	Gabriele Simontacchi, Beatrice Detti, V. Di Cataldo, R. Doro, Giulio Nicita, C. Iermano, Icro Meattini, Marco Carini, Sergio Serni, L. Di Brina, Davide Franceschini, Lorenzo Livi, I. Bonucci, M. Baki, Pierluigi Bonomo, Laura Masi, Samantha Cipressi
Rok vydání:	2015
Předmět:	Biochemical recurrence Male Cancer Research medicine.medical_specialty Disease Radiosurgery Prostate cancer Robotic Surgical Procedures Cyberknife medicine Humans Radiation Injuries Aged Neoplasm Staging Aged 80 and over Genitourinary system business.industry Prostate Prostatic Neoplasms General Medicine Middle Aged medicine.disease Acute proctitis Surgery Oncology Toxicity Radiology business Intermediate risk
Zdroj:	Cancer investigation. 33(5)
ISSN:	1532-4192
Popis:	Cyberknife is an emerging treatment for early stage prostate cancer. Between October 2012 and January 2014, 32 patients were treated in our institution. Prescribed dose was 35-36.25 Gy in five fractions. Biochemical response was observed in 22 patients. Four patients experienced G2 acute genitourinary toxicity and in two cases we recorded G3 acute GU toxicity. 5 patients experienced G2 acute proctitis. At last follow up visit, all patients were still alive. 29 remained free of disease at last follow up appointment, while three developed a biochemical recurrence. Our experience confirms the efficacy and safety of Cyberknife for localized prostate cancer.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a080fbb767c6830775e762ff69ce2647 https://pubmed.ncbi.nlm.nih.gov/25831274 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.